Inactive Instrument

Aquinox Pharmaceuticals Inc Stock price Nasdaq

Equities

US03842B1017

Sales 2024 * - Sales 2025 * - Capitalization 633M
Net income 2024 * -61M Net income 2025 * -76M EV / Sales 2024 * -
Net cash position 2024 * 327M Net cash position 2025 * 501M EV / Sales 2025 * -
P/E ratio 2024 *
-13.2 x
P/E ratio 2025 *
-13.1 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Aquinox Pharmaceuticals Inc

Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in providing immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. The Company uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Its primarily focused on key cytokine mimetics, which it refers to as Neoleukin de novo cytokine mimetics. The Company operates through the research and development of de novo protein therapeutics using sophisticated computational algorithms and methods to address unmet medical needs. The Company's primary areas of focus are on oncology, inflammation, and autoimmunity. Its de novo protein design process uses a set of advanced computational algorithms and methods to design functional de novo proteins.
Sector
-
More about the company
  1. Stock
  2. Equities
  3. Stock Neurogene Inc.
  4. Stock Aquinox Pharmaceuticals Inc - Nasdaq